NCT07251829

Neoadjuvant Embolization and Cytoreduction in Prostate Cancer

Neoadjuvant Embolization and Cytoreduction to Ameliorate Radiotherapy Toxicity in Prostate Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Srinivas Raman · Academic / Other
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to find out whether prostate artery embolization (PAE) can help prevent or lessen urinary side effects caused by radiotherapy (RT) in people with prostate cancer, especially those who have larger prostates or urinary symptoms before treatment. The main questions this study aims to answer are: * Does PAE before RT reduce the severity of urinary side effects from RT? * Does PAE affect the rates of genitourinary (GU) or gastrointestinal (GI) side effects after RT? Researchers will look at changes in urinary symptoms from the start of the study to 6 months after PAE. They will also record any GU or GI side effects related to RT. Participants will receive prostate artery embolization before starting radiotherapy, and complete questionnaires and assessments about GU and GI functions before and after treatment.

Conditions

• Prostate Adenocarcinoma

Interventions

Type	Name	Description
PROCEDURE	Prostatic Artery Embolization	PAE is a minimally invasive procedure that involves embolizing the arteries supplying the prostate, leading to its shrinkage.

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-07-01
• Completion: 2027-12-01
• First posted: 2025-11-26
• Last updated: 2025-11-26